Melanocyte signaling pathways and the etiology of melanoma

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 2, 2005, Pages 179-183

  Wagner, Andrew J ^a   Fisher, David E ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA CATENIN; CYCLIN DEPENDENT KINASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RAF PROTEIN; RAS PROTEIN; SORAFENIB;

AUTOCRINE EFFECT; CARCINOGENESIS; CELL MATURATION; CELL PROLIFERATION; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; GENE AMPLIFICATION; GENE MUTATION; HUMAN; MELANOCYTE; MELANOMA; MONOTHERAPY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR INTRINSIC ACTIVITY; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 33645083465     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.05.017     Document Type: Review

References (33)

1. R. Halaban Growth factors and melanomas Semin. Oncol. 23 1996 673-681
2. J. Du et. al. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma Am. J. Pathol. 163 2003 333-343
3. J. Du et. al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF Cancer Cell 6 2004 565-576
4. G.G. McGill et. al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability Cell 109 2002 707-718
5. S. Carreira et. al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression Nature 433 2005 764-769
6. A.E. Loercher et. al. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A J. Cell Biol. 168 2005 35-40
7. H.R. Widlund D.E. Fisher Microphthalamia-associated transcription factor: A critical regulator of pigment cell development and survival Oncogene 22 2003 3035-3041
8. T. Reya H. Clevers Wnt signalling in stem cells and cancer Nature 434 2005 843-850
9. H.R. Widlund et. al. Beta-catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor J. Cell Biol. 158 2002 1079-1087
10. T.J. Hemesath et. al. MAP kinase links the transcription factor microphthalmia to c-Kit signalling in melanocytes Nature 391 1998 298-301
11. H. Davies et. al. Mutations of the BRAF gene in human cancer Nature 417 2002 949-954
12. P.M. Pollock et. al. High frequency of BRAF mutations in nevi Nat. Genet. 33 2003 19-20
13. S.R. Hingorani et. al. Suppression of BRAF(V599E) in human melanoma abrogates transformation Cancer Res. 63 2003 5198-5202
14. C. Wellbrock et. al. V599EB-RAF is an oncogene in melanocytes Cancer Res. 64 2004 2338-2342
15. T. Ahmad et. al. BAY 43-9006 in patients with advanced melanoma: The Royal Marsden experience J. Clin. Oncol. 22 2004 7506
16. A. Demunter et. al. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma J. Invest. Dermatol. 117 2001 1483-1489
17. Y. Samuels et. al. High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
18. L. Chin et. al. Malignant melanoma: Modern black plague and genetic black box Genes Dev. 12 1998 3467-3481
19. H. Tsao et. al. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines Oncogene 16 1998 3397-3402
20. H. Tsao et. al. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma J. Invest. Dermatol. 122 2004 337-341
21. H. Tsao et. al. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines Cancer Res. 60 2000 1800-1804
22. J.M. Stahl et. al. Loss of PTEN promotes tumor development in malignant melanoma Cancer Res. 63 2003 2881-2890
23. J.M. Stahl et. al. Deregulated Akt3 activity promotes development of malignant melanoma Cancer Res. 64 2004 7002-7010
24. D.L. Dai et. al. Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases J. Clin. Oncol. 23 2005 1473-1482
25. Garraway, L.A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (in press)
26. R. Halaban et. al. Met and hepatocyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells Oncogene 7 1992 2195-2206
27. G. Li et. al. Downregulation of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma development Oncogene 20 2001 8125-8135
28. M. Ozen et. al. Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor Melanoma Res. 14 2004 13-21
29. Y. Wang D. Becker Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth Nat. Med. 3 1997 887-893
30. A. Yayon et. al. Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor 1: Evidence for the involvement of Src-family kinases Oncogene 14 2002 2999-3009
31. E.R. Sauter et. al. Cyclin D1 is a candidate oncogene in cutaneous melanoma Cancer Res. 62 2002 3200-3206
32. D.L. Rimm et. al. Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma Am. J. Pathol. 154 1999 325-329
33. B. Rubinfeld et. al. Stabilization of beta-catenin by genetic defects in melanoma cell lines Science 275 1997 1790-1792